title: Sensitization of vanilloid receptor 1 induced by bradykinin via the activation of second messenger signaling cascades in rat primary afferent neurons.
abstract: Vanilloid receptor 1 was recently reported to play an important role in hyperalgesia, but the mechanisms by which this receptor is activated by endogenous inflammatory mediators, such as bradykinin and nerve growth factor, are not yet fully understood. Here, we investigated whether bradykinin, which is a pain-producing inflammatory mediator, sensitizes vanilloid receptor 1 by inducing the activation of cyclooxygenases, phospholipase C and phospholipase A2 in rat dorsal root ganglion cells. We demonstrated this using 45Ca2+ uptake and inositol phosphates accumulation assays, bradykinin activates phospholipase C and cyclooxygenase-1 through the bradykinin B2 receptor. The bradykinin B2 receptor then sensitizes vanilloid receptor 1 activity by facilitating non-selective Ca2+ channel activity, increasing the intracellular Ca2+ concentration from the extracellular pool. These methods would be useful for screening new drugs for activity at vanilloid receptor 1. These data suggest that endogenous substances produced by several enzymes may be capable of producing a synergistic response involving the vanilloid receptor 1.
authors.affiliation: Department of Pharmacology, Graduate School of Biomedical Sciences, Hiroshima University, Kasumi 1-2-3, Minami-ku, Hiroshima 734-8551, Japan.
authors.forename: He-Bin
authors.initials: HB
authors.lastname: Tang
authors.forename: Atsuko
authors.initials: A
authors.lastname: Inoue
authors.forename: Kyoko
authors.initials: K
authors.lastname: Oshita
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Nakata
mesh_terms: D000818:Animals; D001095:Arachidonic Acids / Q000494:pharmacology; D001920:Bradykinin / Q000494:pharmacology*; D002118:Calcium / Q000493:pharmacokinetics; D002132:Calcium Radioisotopes; D002211:Capsaicin / Q000494:pharmacology; D002478:Cells, Cultured; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004963:Estrenes / Q000494:pharmacology; D005727:Ganglia, Spinal / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D007213:Indomethacin / Q000494:pharmacology; D007295:Inositol Phosphates / Q000378:metabolism; D007473:Ion Channels / Q000378:metabolism*; D009475:Neurons, Afferent / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D009578:Nitrobenzenes / Q000494:pharmacology; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology; D010741:Phospholipases A / Q000037:antagonists & inhibitors; D054467:Phospholipases A2; D011720:Pyrazoles / Q000494:pharmacology; D011760:Pyrrolidinones / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D015290:Second Messenger Systems / Q000502:physiology*; D015398:Signal Transduction / Q000187:drug effects*; D013449:Sulfonamides / Q000494:pharmacology; D050916:TRPV Cation Channels; D010738:Type C Phospholipases / Q000037:antagonists & inhibitors
chemical_list: D001095:Arachidonic Acids; D002132:Calcium Radioisotopes; D016861:Cyclooxygenase Inhibitors; D004963:Estrenes; D007295:Inositol Phosphates; D007473:Ion Channels; D009578:Nitrobenzenes; D010726:Phosphodiesterase Inhibitors; D011720:Pyrazoles; D011760:Pyrrolidinones; C115461:SC 560; D013449:Sulfonamides; D050916:TRPV Cation Channels; C493922:Trpv1 protein, rat; C081565:arachidonyltrifluoromethane; C060229:1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione; C080955:N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide; D010741:Phospholipases A; D054467:Phospholipases A2; D010738:Type C Phospholipases; D002211:Capsaicin; D001920:Bradykinin; D002118:Calcium; D007213:Indomethacin